Cerus Stock Price, News & Analysis (NASDAQ:CERS)

$3.71 -0.09 (-2.37 %)
(As of 12/15/2017 10:42 AM ET)
Previous Close$3.80
Today's Range$3.68 - $3.83
52-Week Range$1.93 - $5.16
Volume440,900 shs
Average Volume966,076 shs
Market Capitalization$433.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.93

About Cerus (NASDAQ:CERS)

Cerus logoCerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Devices & Implants
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:CERS
CUSIP15708510
Phone925-288-6000

Debt

Debt-to-Equity Ratio0.80%
Current Ratio3.71%
Quick Ratio3.11%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$39.28 million
Price / Sales10.78
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book6.63

Profitability

Trailing EPS($0.59)
Net Income$-62,900,000.00
Net Margins-159.35%
Return on Equity-142.18%
Return on Assets-67.72%

Miscellaneous

Employees204
Outstanding Shares114,090,000

Cerus (NASDAQ:CERS) Frequently Asked Questions

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus' earnings last quarter?

Cerus Corporation (NASDAQ:CERS) issued its earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.03. The biotechnology company earned $10.80 million during the quarter, compared to analyst estimates of $11.95 million. Cerus had a negative return on equity of 142.18% and a negative net margin of 159.35%. The firm's quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.14) EPS. View Cerus' Earnings History.

When will Cerus make its next earnings announcement?

Cerus is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Cerus.

Where is Cerus' stock going? Where will Cerus' stock price be in 2017?

5 analysts have issued 12 month target prices for Cerus' shares. Their predictions range from $5.00 to $10.00. On average, they expect Cerus' stock price to reach $6.60 in the next twelve months. View Analyst Ratings for Cerus.

What are Wall Street analysts saying about Cerus stock?

Here are some recent quotes from research analysts about Cerus stock:

  • 1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (11/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $9 PT following mixed 4Q16 results and strong 2017 guidance. The company reports that 55 U.S. hospitals have begun receiving INTERCEPT platelets, with a pipeline of ~10 more expected in 1Q17 and additional hospitals expected in 2Q17. Driving that adoption is the key to 2017, in our view, and the company is sharply focused on driving hospital adoption through expanded medical science liaisons and hospital implementation teams. That said, some hospitals are already ordering as many units as are available and others are not yet in use due to capacity constraints, which we expect to be alleviated as more of the 36 installed systems come online. We continue to believe 2017 may be a breakout year as U.S. INTERCEPT utilization drives kit sales and the company progresses with both its U.S. and European red blood cell programs." (3/8/2017)

Who are some of Cerus' key competitors?

Who are Cerus' key executives?

Cerus' management team includes the folowing people:

  • Daniel N. Swisher Jr., Independent Chairman of the Board (Age 54)
  • William M. Greenman, President, Chief Executive Officer, Director (Age 50)
  • Kevin D. Green, Chief Financial Officer, Vice President - Finance (Age 43)
  • Caspar Hogeboom, President, Cerus Europe and EEMEA (Age 56)
  • Laurence M. Corash M.D., Senior Vice President, Chief Medical and Chief Scientific Officer, Director (Age 71)
  • Carol M. Moore, Senior Vice President - Regulatory Affairs, Quality and Clinical (Age 65)
  • Richard J. Benjamin, Chief Medical Officer
  • Vivek K. Jayaraman, Chief Commercial Officer (Age 41)
  • Chrystal N. Menard, Chief Legal Officer and General Counsel (Age 44)
  • Timothy Bruce Anderson, Independent Director (Age 68)

Who owns Cerus stock?

Cerus' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Elk Creek Partners LLC (5.37%), Senvest Management LLC (2.59%), Peregrine Capital Management LLC (2.58%), First Midwest Bank Trust Division (0.99%), Schwab Charles Investment Management Inc. (0.35%) and Macquarie Group Ltd. (0.20%). Company insiders that own Cerus stock include Carol Moore, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

Who sold Cerus stock? Who is selling Cerus stock?

Cerus' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Peregrine Capital Management LLC, Macquarie Group Ltd. and California State Teachers Retirement System. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Kevin Dennis Green, Richard J Benjamin and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Who bought Cerus stock? Who is buying Cerus stock?

Cerus' stock was bought by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, First Midwest Bank Trust Division, Premier Asset Management LLC, Turner Investments LLC, BB&T Securities LLC, Schwab Charles Investment Management Inc. and Senvest Management LLC. View Insider Buying and Selling for Cerus.

How do I buy Cerus stock?

Shares of Cerus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cerus' stock price today?

One share of Cerus stock can currently be purchased for approximately $3.71.

How big of a company is Cerus?

Cerus has a market capitalization of $433.53 million and generates $39.28 million in revenue each year. The biotechnology company earns $-62,900,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. Cerus employs 204 workers across the globe.

How can I contact Cerus?

Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]


MarketBeat Community Rating for Cerus (CERS)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  286 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cerus (NASDAQ:CERS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.803.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.60$7.60$7.80$7.80
Price Target Upside: 80.82% upside151.66% upside231.91% upside231.91% upside

Cerus (NASDAQ:CERS) Consensus Price Target History

Price Target History for Cerus (NASDAQ:CERS)

Cerus (NASDAQ:CERS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017BTIG ResearchReiterated RatingNeutral -> NeutralLowView Rating Details
12/1/2017Robert W. BairdReiterated RatingBuy$5.00LowView Rating Details
10/5/2017CowenSet Price TargetBuy$6.00N/AView Rating Details
6/7/2017Cantor FitzgeraldReiterated RatingBuy$7.00HighView Rating Details
3/8/2017FBR & CoSet Price TargetBuy$10.00LowView Rating Details
2/6/2016StephensReiterated RatingBuyN/AView Rating Details
12/17/2015WedbushDowngradeOutperform -> Neutral$6.50N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Cerus (NASDAQ:CERS) Earnings History and Estimates Chart

Earnings by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ CERS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018        
11/2/2017Q3 2017($0.15)($0.12)$11.95 million$10.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.16)($0.16)$9.14 million$9.53 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.17)($0.18)$8.98 million$7.01 millionViewListenView Earnings Details
3/7/2017Q4 2016($0.16)($0.13)$11.29 million$10.10 millionViewListenView Earnings Details
11/3/2016Q316($0.17)($0.14)$10.34 million$10.20 millionViewN/AView Earnings Details
8/4/2016Q216($0.17)($0.18)$8.88 million$9.25 millionViewN/AView Earnings Details
5/3/2016Q1($0.16)($0.17)$8.29 million$7.60 millionViewN/AView Earnings Details
3/8/2016Q415($0.16)($0.15)$9.72 million$9.70 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.17)$10.00 million$8.04 millionViewN/AView Earnings Details
8/6/2015Q215($0.15)($0.17)$8.71 million$8.83 millionViewN/AView Earnings Details
5/5/2015Q214($0.16)($0.21)$7.70 million$7.70 millionViewN/AView Earnings Details
2/26/2015Q114($0.15)($0.25)$10.36 million$9.70 millionViewN/AView Earnings Details
11/4/2014Q413($0.13)($0.15)$9.83 million$10.36 millionViewN/AView Earnings Details
7/31/2014Q313($0.13)($0.16)$8.17 million$8.60 millionViewN/AView Earnings Details
5/1/2014Q313($0.09)($0.04)$9.65 million$7.86 millionViewN/AView Earnings Details
2/25/2014Q213($0.09)($0.10)$11.77 million$9.23 millionViewN/AView Earnings Details
10/29/2013($0.09)($0.29)$10.34 million$10.54 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Cerus (NASDAQ:CERS) Earnings Estimates

2017 EPS Consensus Estimate: ($0.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.15)($0.15)($0.15)
Q2 20171($0.14)($0.14)($0.14)
Q3 20171($0.13)($0.13)($0.13)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cerus (NASDAQ:CERS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Cerus (NASDAQ CERS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 58.46%
Insider Trades by Quarter for Cerus (NASDAQ:CERS)
Insider Trades by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ CERS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Laurence M CorashInsiderBuy92,796$2.45$227,350.20View SEC Filing  
3/15/2017Kevin Dennis GreenCFOSell2,343$4.21$9,864.03View SEC Filing  
3/15/2017William Mariner GreenmanInsiderSell8,786$4.21$36,989.06View SEC Filing  
3/14/2017Carol MooreSVPSell2,377$4.15$9,864.55View SEC Filing  
3/14/2017Richard J BenjaminInsiderSell1,189$4.15$4,934.35View SEC Filing  
8/22/2016Kevin Dennis GreenCFOSell17,150$6.80$116,620.00View SEC Filing  
8/19/2015Laurence M CorashInsiderBuy25,900$4.99$129,241.00View SEC Filing  
8/18/2015Laurence M CorashInsiderBuy84,600$4.77$403,542.00View SEC Filing  
11/10/2014William Mariner GreenmanCEOBuy21,800$3.93$85,674.00View SEC Filing  
11/19/2012William Mariner GreenmanCEOBuy3,200$3.02$9,664.00View SEC Filing  
11/16/2012Laurence M CorashInsiderBuy2,000$2.85$5,700.00View SEC Filing  
11/16/2012William Mariner GreenmanCEOBuy13,800$2.85$39,330.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cerus (NASDAQ CERS) News Headlines

Source:
DateHeadline
Does Cerus Energy Group Ltd’s (CVE:CEA) Recent Track Record Look Strong?Does Cerus Energy Group Ltd’s (CVE:CEA) Recent Track Record Look Strong?
finance.yahoo.com - December 12 at 5:49 PM
Cerus (CERS) vs. Its Rivals Critical AnalysisCerus (CERS) vs. Its Rivals Critical Analysis
www.americanbankingnews.com - December 9 at 11:42 PM
Cerus (CERS) "Neutral" Rating Reaffirmed at BTIG ResearchCerus' (CERS) "Neutral" Rating Reaffirmed at BTIG Research
www.americanbankingnews.com - December 8 at 6:08 PM
Head-To-Head Review: Cerus (CERS) versus The CompetitionHead-To-Head Review: Cerus (CERS) versus The Competition
www.americanbankingnews.com - December 7 at 9:38 PM
Cerus (CERS) versus Its Competitors Financial AnalysisCerus (CERS) versus Its Competitors Financial Analysis
www.americanbankingnews.com - December 6 at 7:25 PM
Contrasting Cerus (CERS) & Its PeersContrasting Cerus (CERS) & Its Peers
www.americanbankingnews.com - December 6 at 7:24 PM
Head-To-Head Analysis: Cerus (CERS) versus Its RivalsHead-To-Head Analysis: Cerus (CERS) versus Its Rivals
www.americanbankingnews.com - December 5 at 9:26 PM
Cerus (CERS) vs. Its Competitors Critical ComparisonCerus (CERS) vs. Its Competitors Critical Comparison
www.americanbankingnews.com - December 4 at 8:44 AM
Contrasting Cerus (CERS) and Its RivalsContrasting Cerus (CERS) and Its Rivals
www.americanbankingnews.com - December 4 at 1:34 AM
Cerus (CERS) Given Buy Rating at Robert W. BairdCerus (CERS) Given Buy Rating at Robert W. Baird
www.americanbankingnews.com - December 1 at 8:38 PM
Comparing Cerus (CERS) and Its CompetitorsComparing Cerus (CERS) and Its Competitors
www.americanbankingnews.com - December 1 at 7:30 PM
Reviewing Cerus (CERS) & Its CompetitorsReviewing Cerus (CERS) & Its Competitors
www.americanbankingnews.com - December 1 at 11:16 AM
Cerus Corporation (CERS) Receives Average Recommendation of "Hold" from AnalystsCerus Corporation (CERS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 30 at 9:56 AM
Head to Head Review: Cerus (CERS) and Its RivalsHead to Head Review: Cerus (CERS) and Its Rivals
www.americanbankingnews.com - November 30 at 9:02 AM
Head to Head Contrast: Cerus (CERS) vs. Its CompetitorsHead to Head Contrast: Cerus (CERS) vs. Its Competitors
www.americanbankingnews.com - November 27 at 3:56 PM
Critical Comparison: Cerus Corporation (CERS) & Its RivalsCritical Comparison: Cerus Corporation (CERS) & Its Rivals
www.americanbankingnews.com - November 25 at 9:26 AM
Head-To-Head Comparison: Cerus Corporation (CERS) vs. Its CompetitorsHead-To-Head Comparison: Cerus Corporation (CERS) vs. Its Competitors
www.americanbankingnews.com - November 25 at 3:26 AM
Factors of Influence in 2018, Key Indicators and Opportunity within REV Group, CoreLogic, M/I HomesFactors of Influence in 2018, Key Indicators and Opportunity within REV Group, CoreLogic, M/I Homes
www.nasdaq.com - November 22 at 5:48 PM
Factors of Influence in 2018, Key Indicators and Opportunity within REV Group, CoreLogic, M/I Homes, Halyard Health, Deckers Outdoor, and Cerus — New Research Emphasizes Economic GrowthFactors of Influence in 2018, Key Indicators and Opportunity within REV Group, CoreLogic, M/I Homes, Halyard Health, Deckers Outdoor, and Cerus — New Research Emphasizes Economic Growth
finance.yahoo.com - November 22 at 5:48 PM
Contrasting Cerus Corporation (CERS) and The CompetitionContrasting Cerus Corporation (CERS) and The Competition
www.americanbankingnews.com - November 22 at 11:31 AM
Analyzing Cerus (CERS) and Its RivalsAnalyzing Cerus (CERS) and Its Rivals
www.americanbankingnews.com - November 20 at 3:20 PM
Who Are The Largest Shareholders In Cerus Energy Group Ltd (TSXV:CEA)?Who Are The Largest Shareholders In Cerus Energy Group Ltd (TSXV:CEA)?
finance.yahoo.com - November 17 at 4:27 PM
Zacks.com highlights: Drive Shack, Cerus, ReWalk Robotics, Aerohive Networks and Cloud Peak EnergyZacks.com highlights: Drive Shack, Cerus, ReWalk Robotics, Aerohive Networks and Cloud Peak Energy
finance.yahoo.com - November 16 at 12:36 PM
Financial Survey: Cerus Corporation (CERS) vs. The CompetitionFinancial Survey: Cerus Corporation (CERS) vs. The Competition
www.americanbankingnews.com - November 15 at 3:30 PM
5 Breakout Stocks Offering Admirable Returns5 Breakout Stocks Offering Admirable Returns
finance.yahoo.com - November 14 at 5:35 PM
Cerus Corporation (CERS) vs. Its Peers Critical ReviewCerus Corporation (CERS) vs. Its Peers Critical Review
www.americanbankingnews.com - November 11 at 1:28 AM
Cerus Corporation (CERS) and Its Peers Critical ReviewCerus Corporation (CERS) and Its Peers Critical Review
www.americanbankingnews.com - November 10 at 5:22 AM
Cerus Corporation (CERS) Upgraded by Zacks Investment Research to BuyCerus Corporation (CERS) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - November 8 at 9:10 PM
Cerus (CERS) Receives IDE Approval to Initiate Phase III ReCePI StudyCerus (CERS) Receives IDE Approval to Initiate Phase III ReCePI Study
www.streetinsider.com - November 8 at 1:08 AM
Cerus Corporation Receives IDE Approval to Initiate Phase III ReCePI StudyCerus Corporation Receives IDE Approval to Initiate Phase III ReCePI Study
finance.yahoo.com - November 8 at 1:08 AM
Cerus (CERS) Receives IDE Approval to Initiate Phase III ReCePI Study - StreetInsider.comCerus (CERS) Receives IDE Approval to Initiate Phase III ReCePI Study - StreetInsider.com
www.streetinsider.com - November 7 at 8:06 PM
Cerus Corporation (CERS) Receives Consensus Rating of "Hold" from BrokeragesCerus Corporation (CERS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 5 at 11:58 AM
Edited Transcript of CERS earnings conference call or presentation 2-Nov-17 8:15pm GMTEdited Transcript of CERS earnings conference call or presentation 2-Nov-17 8:15pm GMT
finance.yahoo.com - November 3 at 5:48 PM
Here's Why Cerus Corporation Rose as Much as 23.6% TodayHere's Why Cerus Corporation Rose as Much as 23.6% Today
finance.yahoo.com - November 3 at 5:48 PM
Heres Why Cerus Corporation Rose as Much as 23.6% TodayHere's Why Cerus Corporation Rose as Much as 23.6% Today
www.fool.com - November 3 at 1:53 PM
Cerus (CERS) CEO Obi Greenman on Q3 2017 Results - Earnings ... - Seeking AlphaCerus' (CERS) CEO Obi Greenman on Q3 2017 Results - Earnings ... - Seeking Alpha
seekingalpha.com - November 3 at 8:01 AM
Cerus Corporation (CERS) Releases  Earnings Results, Beats Expectations By $0.04 EPSCerus Corporation (CERS) Releases Earnings Results, Beats Expectations By $0.04 EPS
www.americanbankingnews.com - November 3 at 12:46 AM
Cerus Corporation Reports Third Quarter 2017 Results | Business ... - Business Wire (press release)Cerus Corporation Reports Third Quarter 2017 Results | Business ... - Business Wire (press release)
www.businesswire.com - November 2 at 10:52 PM
Cerus Corporation Reports Third Quarter 2017 ResultsCerus Corporation Reports Third Quarter 2017 Results
finance.yahoo.com - November 2 at 5:51 PM
Cerus reports 3Q lossCerus reports 3Q loss
finance.yahoo.com - November 2 at 5:51 PM
Should You Be Concerned About Cerus Energy Group Ltd’s (TSXV:CEA) Risks?Should You Be Concerned About Cerus Energy Group Ltd’s (TSXV:CEA) Risks?
finance.yahoo.com - November 1 at 5:53 PM
Cerus (CERS), Kedrion Biopharma Enter Distribution Pact for Full INTERCEPT Blood System Portfolio in ItalyCerus (CERS), Kedrion Biopharma Enter Distribution Pact for Full INTERCEPT Blood System Portfolio in Italy
www.streetinsider.com - October 31 at 6:13 PM
Cerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System Portfolio in ItalyCerus and Kedrion Biopharma Enter Distribution Agreement for the Full INTERCEPT Blood System Portfolio in Italy
finance.yahoo.com - October 31 at 6:13 PM
Cerus Announces Agreement with Transfusion Center of the Community of Madrid - Business Wire (press release)Cerus Announces Agreement with Transfusion Center of the Community of Madrid - Business Wire (press release)
www.businesswire.com - October 30 at 3:43 PM
Cerus Announces Agreement with Transfusion Center of the Community of MadridCerus Announces Agreement with Transfusion Center of the Community of Madrid
finance.yahoo.com - October 30 at 3:42 PM
ETFs with exposure to Cerus Corp. : October 30, 2017ETFs with exposure to Cerus Corp. : October 30, 2017
finance.yahoo.com - October 30 at 3:42 PM
Cerus Corporation (CERS) Set to Announce Quarterly Earnings on ThursdayCerus Corporation (CERS) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - October 26 at 6:10 AM
Cerus (CERS) Reports German Reimbursement for Pathogen Inactivated PlateletsCerus (CERS) Reports German Reimbursement for Pathogen Inactivated Platelets
www.streetinsider.com - October 25 at 5:27 AM
Cerus (CERS) Reports German Reimbursement for Pathogen Inactivated Platelets - StreetInsider.comCerus (CERS) Reports German Reimbursement for Pathogen Inactivated Platelets - StreetInsider.com
www.streetinsider.com - October 24 at 7:08 AM
Cerus Announces National German Reimbursement for Pathogen Inactivated PlateletsCerus Announces National German Reimbursement for Pathogen Inactivated Platelets
finance.yahoo.com - October 23 at 4:03 PM

SEC Filings

Cerus (NASDAQ:CERS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cerus (NASDAQ:CERS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cerus (NASDAQ CERS) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.